Thanks to a study done in Lille, we know more about the genetic factors of the disease.


Better understand the causes of this pathology in order to better treat it. This is the purpose of this study, which reveals new genetic factors for the disease.

A major advance in Alzheimer’s research. In particular, a study conducted by an international consortium of researchers within the Pasteur Institute in Lille reveals that 42 new genes associated with this disease have been identified. This discovery raises hopes of finding a cure for years to come to combat this scourge, which affects nearly 1,200,000 people in France.

“In the field of genetics, these advances are the most important advances in Alzheimer’s disease in recent years”, Says Jean-Charles Lambert, director of research at Inserm, who led this study.

This research determined 75 genes, 42 of which are associated with this pathology new has never been before detected. “We are doubling our knowledge of the genetics of Alzheimer’s, says the researcher. After this discovery, the remainder of our work consisted of characterizing these regions of the genome that we had identified in order to make sense of them in relation to our biological and clinical knowledge and thus to better understand the cellular mechanisms and pathological processes at work. ”

These results are clear new avenues for therapeutic research. “There are several ways to develop a variety of treatments to be targeted, says Jean-Charles Lambert. Genetics shows that a monotherapeutic approach is not possible, it must be polytherapeutic. There won’t be a miracle drug, there won’t be a single cure.”

One of these pathways would be the inflammatory response in the individual. “We must control it and block it as soon as possible”, explains. The good news is there are already clinical trials on the subject, maybe this will speed it up to develop an appropriate treatment.

Be warned, there is no cure for now. “It will take 5 to 10 years to deliver therapeutic components tested in clinical trials”, says Jean-Charles Lambert.

Make no mistake, Alzheimer’s is not inherited. “Just because someone in your family has the disease doesn’t mean you’ll get it. He remembers the Inserm researcher. This is not a death.” However, a person’s genetic component may strengthen the predisposition to develop the pathology. “Represents 60 to 80% of attributable risk, the rest are modifiable risk factors (diabetes, obesity, diet, sports practices).

To improve therapeutic responses, the researchers created a “genetic risk score.” “This makes it possible to assess the probability that this person will develop Alzheimer’s disease, based on the individual’s genetic heritage”, explains. A tool for professionals to accelerate research on treatments to be developed. “The point of the game is not to screen, but when a patient notices one of the Alzheimer’s symptoms at home, they can come and consult.”

“As treatments become available, the question will be: when and to whom should these therapies be given?” asks the researcher. In this context, the calculation of the genetic score will actually enable the delivery of the best therapeutic care.

To date, only one treatment (a type of immunotherapy) is available to combat this disease: aducanumab. However, the latter is controversial. Not recognized by the European Medicines Agency if authorized in the United States.

The study was conducted by researchers from Inserm, Institut Pasteur de Lille, University Hospital Lille and the University of Lille in the laboratory U1167 “molecular risk factors and determinants of aging-related diseases”. an international consortium.

never The largest group of Alzheimer’s patients for a study of this disease: 111,326 cases have been investigated worldwide and there are many witnesses. The results were published in the scientific journal NatureGenetics.